Stimulating pharmaceutical research and development for neglected diseases
被引:24
|
作者:
Mrazek, MF
论文数: 0引用数: 0
h-index: 0
机构:
Univ London London Sch Econ & Polit Sci, LSE Hlth & Social Care, London WC2A 2AE, EnglandUniv London London Sch Econ & Polit Sci, LSE Hlth & Social Care, London WC2A 2AE, England
Mrazek, MF
[1
]
Mossialos, E
论文数: 0引用数: 0
h-index: 0
机构:
Univ London London Sch Econ & Polit Sci, LSE Hlth & Social Care, London WC2A 2AE, EnglandUniv London London Sch Econ & Polit Sci, LSE Hlth & Social Care, London WC2A 2AE, England
Mossialos, E
[1
]
机构:
[1] Univ London London Sch Econ & Polit Sci, LSE Hlth & Social Care, London WC2A 2AE, England
neglected diseases;
pharmaceutical research and development;
public-private partnerships;
PUBLIC-PRIVATE PARTNERSHIPS;
INFECTIOUS-DISEASES;
COUNTRIES;
DRUGS;
TUBERCULOSIS;
MALARIA;
WORLD;
D O I:
10.1016/S0168-8510(02)00138-0
中图分类号:
R19 [保健组织与事业(卫生事业管理)];
学科分类号:
摘要:
New vaccines and drug treatments are needed for tackling the neglected diseases (NDs) of poor countries. These diseases are associated with high levels of mortality and/or morbidity, but lack appropriate vaccines and drug treatments because of bacterial resistance, toxicity, long-treatment protocols, problems with administration or because none are available. Current initiatives directed at research and development (R&D) of NDs are being led predominantly by the governmental, inter-governmental and private not-for-profit sectors implemented by way of public-private partnerships. Push and pull mechanisms targeted at the pharmaceutical industry have also been proposed as another way to stimulate RD of NDs; however, these should be viewed with some caution. Stimulating R&D for NDs is important as part of a wider long-term public health strategy and must be addressed simultaneously with resolving more immediate problems of access to medicines and health system sustainability in less developed countries. (C) 2002 Published by Elsevier Science Ireland Ltd.
机构:
WHO, Expert Working Grp Res & Dev Financing, CH-1211 Geneva 27, SwitzerlandWHO, Expert Working Grp Res & Dev Financing, CH-1211 Geneva 27, Switzerland